Target intelligence / Profile preview

Methyltransferase-like protein 14 (METTL14)

Target
METTL14
Molecular classification
Enzyme, Other
01

Overview

Methyltransferase-like protein 14 (METTL14) is a critical non-catalytic subunit of the N6-methyladenosine (m6A) methyltransferase complex, which also includes the catalytic subunit METTL3 and the regulatory protein WTAP. METTL14 acts as an essential structural scaffold that binds to substrate RNA and stabilizes the complex, facilitating the deposition of m6A modifications on mRNA and non-coding RNAs. This epitranscriptomic modification plays a pivotal role in regulating RNA processing, splicing, stability, and translation, thereby controlling key cellular processes such as stem cell pluripotency, cell differentiation, and immune responses.\n\nIn oncology, METTL14 is frequently dysregulated and can act as either an oncogene or a tumor suppressor depending on the cellular context. It is highly implicated in acute myeloid leukemia (AML), breast cancer, glioblastoma, and colorectal cancer, where it promotes tumor cell proliferation, metastasis, and resistance to therapies like CDK4/6 inhibitors. Furthermore, METTL14 modulates the tumor immune microenvironment by regulating immune checkpoint molecules such as PD-L1, making it a promising target for combination therapies with immune checkpoint inhibitors. Therapeutic strategies targeting METTL14 include small-molecule inhibitors (e.g., WKYMVM), PROTAC degraders (e.g., WD6305), and complex inhibitors (e.g., STM2457, RSM3) that disrupt the METTL3-METTL14 interaction or degrade the complex to suppress oncogenic signaling.

Other names
N(6)-adenosine-methyltransferase non-catalytic subunit METTL14Methyltransferase-like 14hmethyltransferase 14Karyogamy protein 4
02

Mechanism of action

Inhibition of the m6A methyltransferase complex, degradation of the METTL3-METTL14 complex, or disruption of the METTL3-METTL14 interaction

03

Biological functions

Cell cycleApoptosisImmune responseCell proliferationCell deathOther
04

Disease associations

CancerInfectionNeurodegenerative diseaseOther
05

Safety considerations

Impairment of normal hematopoiesisDisruption of embryonic stem cell differentiationAlterations in circadian rhythmPotential immune system dysregulationNeurotoxicity or neuropsychiatric side effects
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

METTL14 expression levelm6A RNA methylation levelPD-L1 expressionE2F1 expression

Beyond the preview

Go deeper on Methyltransferase-like protein 14 (METTL14).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Methyltransferase-like protein 14 (METTL14).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call